Skip to main
  1. Stocks
  2. Fractyl Health Inc
  3. Forecast
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is supported by a credible clinical and regulatory inflection point, as Revita met its six-month REMAIN-1 co-primary endpoint with statistically significant weight-regain reduction versus sham (p=0.0023), while participants retained about 80% of GLP-1-induced weight loss and the company targets a late 4Q26 FDA De Novo submission. The durability story is strengthened by REVEAL-1 one-year data showing 78% weight-loss retention, 100% responder performance on the ≥5% maintenance threshold, and no late device-related adverse events, which should help de-risk adoption and reimbursement. Financially, management’s 45% workforce reduction and refocus on Revita are expected to cut quarterly operating cash spending by about 50% to $8 million by the end of 2Q27, preserving runway into 2Q27 while key 1Q27 and 3Q26 data milestones approach.

Bears say

Fractyl Health is burdened by a highly speculative clinical-stage profile, with its valuation dependent on the projected chances of success of Revita and Rejuva rather than any established commercial revenue base. The company faces material binary risks, including failed or inconclusive clinical trials, uncertainty around adding new assets from its platforms, and the possibility that promising data may never translate into approvable therapies. Its financial downside is amplified by the need for adequate funding to advance development, creating exposure to dilutive capital raises and even delisting risk if exchange compliance is not maintained.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

GUTS Analyst Forecast & Price Prediction

Get the latest GUTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GUTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


GUTS Analyst Forecast & Price Prediction

Get the latest GUTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GUTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GUTS stock data and trends